Literature DB >> 7520304

Endothelial activation and chronic allograft rejection.

C G Orosz1.   

Abstract

Microvascular endothelial cells are actively involved in acute and hyperacute allograft rejection. In acute rejection, inflamed graft endothelia increase their expression of cell adhesion and antigen-presentation molecules, thereby initiating and promoting various mechanisms of cellular immune rejection. In hyperacute rejection, preformed antibodies bind to graft endothelial cells and initiate endothelial procoagulant activity. These disparate immune responses appear to reflect different manifestations of endothelial cell activation. We hypothesize that chronic allograft rejection is a third manifestation of local endothelial activation. Chronic rejection is associated with interstitial and/or vascular hypertrophy. It is intriguing that among the products of activated endothelial cells are extracellular matrix components and growth factors that promote tissue reconstruction. This suggests that chronic or repetitive stimulation of endothelial cells may cause persistent or periodic release of these growth factors, eventually leading to the histopathology of chronic rejection. Chronic endothelial stimulation could be accomplished by drugs, alloantibodies, immune mediators, or some combination thereof. This leads to the question: Do different patterns of endothelial stimulation result in different manifestations of endothelial activation? Our studies of acute rejection mechanisms in murine cardiac allografts demonstrated that several stable endothelial phenotypes can develop during graft inflammation, depending on the availability of local immune stimuli (Transplantation 1993: 55: 315). Unpublished studies suggest that the steroids prednisolone and dexamethasone can synergize in vitro with suboptimal concentrations of interferon-gamma (IFN-gamma) to promote the activation of human endothelial cell lines, as manifested by enhanced expression of MHC class II but not ICAM-1. These steroids do not influence tumor necrosis factor-alpha (TNF-alpha)-induced endothelial behavior.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520304

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

Review 1.  Diagnosis and management of late complications after liver transplantation.

Authors:  G Noble-Jamieson; N Barnes
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

2.  A two-step model of acute CD4 T-cell mediated cardiac allograft rejection.

Authors:  Todd J Grazia; Biagio A Pietra; Zachary A Johnson; Brian P Kelly; Robert J Plenter; Ronald G Gill
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

Review 3.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

4.  Pathology of Chronic Rejection: An Overview of Common Findings and Observations About Pathogenic Mechanisms and Possible Prevention.

Authors:  A J Demetris; N Murase; T E Starzl; J J Fung
Journal:  Graft (Georget Tex)       Date:  1998-05

Review 5.  [Immunologic, alloantigen-dependent factors in chronic graft rejection].

Authors:  C Barth; J Stachowski; A von Menges; P Lammerding; C A Baldamus
Journal:  Med Klin (Munich)       Date:  1998-01-15

6.  The frequency and avidity of committed cytotoxic T lymphocytes (cCTL) for donor HLA class I and class II antigens and their relation with graft vascular disease.

Authors:  N M van Besouw; E H Loonen; L M Vaessen; A H Balk; F H Claas; W Weimar
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.